About: SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping
Creator	Kaur, Gagandeep Rahman, Irfan Lungarella, Giuseppe
Source	Medline; PMC
abstract	The current pandemic of COVID-19 has caused severe morbidity and mortality across the globe. People with a smoking history have severe disease outcomes by COVID-19 infection. Epidemiological studies show that old age and pre-existing disease conditions (hypertension and diabetes) result in severe disease outcome and mortality amongst COVID-19 patients. Evidences suggest that the S1 domain of the SARS-CoV-2 (causative agent of COVID-19) membrane spike has a high affinity towards the angiotensin-converting enzyme 2 (ACE2) receptor found on the host’s lung epithelium. Likewise, TMPRSS2 protease has been shown to be crucial for viral activation thus facilitating the viral engulfment. The viral entry has been shown to cause ‘cytokine storm’ involving excessive production of pro-inflammatory cytokines/chemokines including IL-6, TNF-α, IFN-γ, IL-2, IL-7, IP-10, MCP-3 or GM-CSF, which is augmented by smoking. Future research could target these inflammatory-immunological responses to develop effective therapy for COVID-19. This mini-review provides a consolidated account on the role of inflammation and immune responses, proteases, and epithelial permeability by smoking and vaping during SARS-CoV2 infection with future directions of research, and provides a list of the potential targets for therapies particularly controlling cytokine storms in the lung.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.1186/s12950-020-00250-8
bibo:pmid	32528233
has license	cc-by
sha1sum (hex)	8078953d0ba4f3cc25fdfb252af8fecc9a61f796
schema:url	https://doi.org/10.1186/s12950-020-00250-8
resource representing a document's title	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping
has PubMed Central identifier	PMC7284674
has PubMed identifier	32528233
schema:publication	J Inflamm (Lond)
resource representing a document's body	covid:8078953d0ba4f3cc25fdfb252af8fecc9a61f796#body_text
is schema:about of	named entity 'lung' named entity 'develop' named entity 'COVID-19' named entity 'severe' named entity 'result' named entity 'high' named entity 'augmented' named entity 'lung' named entity 'vaping' named entity 'epithelial' named entity 'affinity' named entity 'targets' named entity 'lung' named entity 'smoking' named entity 'Epidemiological studies' named entity 'production' named entity 'patients' named entity 'membrane' named entity 'viral entry' named entity 'lung' named entity 'receptor' named entity 'lung' named entity 'ACE2' named entity 'angiotensin-converting enzyme 2' named entity 'inflammatory' named entity 'SARS-CoV-2' named entity 'Epidemiological studies' named entity 'COVID' named entity 'IL-7' named entity 'immune responses' named entity 'cytokine storms' named entity 'SARS-CoV-2' named entity 'GM-CSF' named entity 'diabetes' named entity 'clinical trials' named entity 'RNA virus' named entity 'Proteases' named entity 'genome' named entity 'SARS-CoV2' named entity 'enzyme' named entity 'BALF' named entity 'China' named entity 'viral replication' named entity 'vaping' named entity 'furin' named entity 'TMPRSS2' named entity 'HGF' named entity 'mechanism of action' named entity 'immune response' named entity 'SARS-CoV2' named entity 'Exosomes' named entity 'COVID' named entity 'miRNA' named entity 'nicotinic acetylcholine receptors' named entity 'spike protein' named entity 'serine protease inhibitors' named entity 'ARDS' named entity 'infection' named entity 'IP-10' named entity 'pathogenesis' named entity 'SARS-CoV2' named entity 'ACE inhibitors' named entity 'vapers' named entity 'epithelial' named entity 'infection' named entity 'case fatality rates' named entity 'vaccine' named entity 'type II pneumocytes' named entity 'vapers' named entity 'alveolar' named entity 'remdesivir' named entity 'vaping' named entity 'virus' named entity 'ciliated' named entity 'immune cell' named entity 'pathogenesis' named entity 'coronaviruses' named entity 'IL-6' named entity 'TMPRSS2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software